Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems develops and commercializes minimally invasive neurostimulation therapy for patients with obstructive sleep apnea. Its proprietary Inspire therapy is approved by the FDA, EU MDR and PDMA for moderate to severe obstructive sleep apnea, and product updates include the Inspire V system.
Company news commonly covers quarterly and annual results, revenue guidance, cash flow, earnings measures, reimbursement and coding developments, product launch activity, regulatory clearances such as MRI compatibility, executive changes and healthcare conference presentations.
Inspire Medical Systems (NYSE: INSP) reported strong 4Q25 and full-year 2025 results, driven by the commercial launch of the Inspire V system and FDA 3.0T MRI compatibility.
Highlights include 4Q revenue $269.1M (+12%), FY revenue $912.0M (+14%), 4Q diluted EPS $4.66, FY diluted EPS $4.89, and operating cash flow of $117.0M for 2025. The company revised 2026 revenue guidance to $950M–$1.0B and noted coding clarification to CPT 64582 with a -52 modifier may affect physician reimbursement.
Inspire Medical Systems (NYSE: INSP) reported preliminary, unaudited revenue of $268.9M–$269.1M for Q4 2025 (≈12% YoY) and $911.8M–$912.0M for full year 2025 (≈14% YoY). The company provided initial 2026 revenue guidance of $1,003M–$1,013M (10%–11% above 2025). Management cited momentum from the Inspire V system launch and noted recent reimbursement developments, but said guidance excludes any reimbursement contribution. Results are preliminary and subject to change pending year-end close and audit.
Inspire Medical Systems (NYSE: INSP) will report fourth quarter and full year 2025 financial results after market close on Wednesday, February 11, 2026. Management will host a conference call at 5:00 p.m. Eastern Time to discuss results and recent business developments.
A live webcast will be available on the company’s Investor Relations page and registration is required to ask questions; registrants receive dial-in details and a unique access code. The company recommends registering at least 10 minutes before the call. A replay will be posted approximately two hours after the event and archived on the Investor Relations site for two weeks.
Inspire Medical Systems (NYSE: INSP) announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 12:45 p.m. Eastern Time.
The presentation will be available via a live webcast, with a replay accessible for two weeks after the event in the Event Archive on Inspire’s investor website: https://investors.inspiresleep.com.
Inspire Medical Systems (NYSE: INSP) announced its management team will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 11:30 a.m. Eastern Time.
The presentation will be available via a live webcast and a replay will be hosted for two weeks in the Event Archive on Inspire’s investor website at https://investors.inspiresleep.com.
Inspire Medical Systems (NYSE: INSP) reported third quarter 2025 results on November 3, 2025, with Q3 revenue of $224.5M (up 10% YoY) and gross margin of 85.8%. The company reported net income of $9.9M and adjusted net income of $11.2M, with diluted EPS of $0.34 and adjusted diluted EPS of $0.38. Operating cash flow for Q3 was $68.5M. Management completed $50M of share repurchases and reported strong early adoption of the Inspire V system with positive clinical and procedural results. Inspire reaffirmed 2025 revenue guidance of $900M–$910M, maintained gross margin guidance of 84%–86%, and raised diluted net income per share guidance to $0.90–$1.00 from $0.40–$0.50.
Inspire Medical Systems (NYSE: INSP) announced that its management will present at the 2025 UBS Global Healthcare Conference on Monday, November 10, 2025 at 11:45 a.m. ET. The presentation will be available via live webcast and a replay will be posted for two weeks in the Event Archive on Inspire’s investor website at https://investors.inspiresleep.com. The session covers the company’s recent business developments and investor outreach at the UBS conference.
Inspire Medical Systems (NYSE: INSP) published clinical and limited-market data for the new Inspire V hypoglossal nerve stimulation system presented at ISSS/AAO-HNS (Oct 9–14, 2025).
Key results: Inspire V showed an IPOP of 87.1% vs 79.4% for Inspire IV, a reported 20% reduction in surgical time, strong adherence (Singapore mean 5.5±1.7 h/night at ~246 days; US limited release mean 6.8 h/night at 60 days) and median AHI reductions from 34.4 to 8.3 events/hour (Singapore, 37 patients at 6 months) and from 30 to 4.5 events/hour (US, first 34 patients).
Safety: no serious adverse events in the US cohort; two Singapore patients required short postoperative antibiotics. Additional patients remain to complete six-month follow-up for publication.
Inspire Medical Systems (NYSE: INSP) will report third quarter 2025 financial results after the close of trading on Monday, November 3, 2025. Management will host a conference call at 5:00 p.m. Eastern Time to discuss results and recent business developments.
A live webcast will be available on the company’s Investor Relations page and registrants who intend to ask questions must register to receive dial‑in details and a unique access code. The company recommends registering at least 10 minutes before the call. A replay will be posted on the Investor Relations site about two hours after the call and will be archived for two weeks.
Inspire Medical Systems (NYSE:INSP), a medical technology company specializing in sleep apnea solutions, announced that CFO Rick Buchholz will step down effective December 31, 2025. Buchholz will continue as a financial advisor through February 28, 2026 to ensure transition.
During Buchholz's tenure since 2014, the company achieved significant milestones, including revenue growth from $4 million to over $800 million in 2024, successful IPO completion, and reaching profitability. The company reaffirmed its 2025 guidance with revenue of $900-910 million, gross margin of 84-86%, and diluted EPS of $0.40-$0.50.